What Does the Evidence Actually Say?
Peptide research. Primary evidence. No shortcuts.
We read the published literature on research peptides and compounds so you don't have to guess — what's been studied, in what model, with what result, and how confident you should actually be about any of it.
Explore the evidence
Three ways into the same underlying standard — pick whichever matches what you're trying to find out.
Evidence Library
Structured, per-compound profiles showing where research stands — preclinical, early human, or further along — with sources attached.
Browse profiles →Clinical Trials Tracker
Registered human trials across the compounds we cover, with direct links to every registry record — no trial listed that we can't point you to.
Browse trials →Compound Deep Dives
Long-form explainers on individual compounds — the full picture, written out, rather than a database entry.
Read the Deep Dives →Start here
A cross-section of what's live right now across the site.
BPC-157
A large preclinical literature and almost no human trial data — the gap that gets glossed over elsewhere.
Retatrutide
A triple-agonist furthest along in human trials of any compound we cover — still investigational, not yet approved.
How we classify evidence
The same preclinical → early clinical → approved framework, applied consistently across every compound profile.
11 verified registered trials
Across 5 compounds, with direct links to every ClinicalTrials.gov record — searchable and filterable.
Most information about research peptides online comes from one of two places: a seller trying to move product, or a forum post repeating something nobody checked. Neither tells you what the actual published evidence says, where it's strong, where it's thin, or where it simply doesn't exist yet.
The Primary Source exists to close that gap. We explain what laboratory, animal, and human research actually shows for a given compound — and we're explicit about the difference, because that difference is usually the whole story. We're not a substitute for reading the primary literature yourself; we're a clearer way in.
The Primary Source is produced and funded by Reliable Research Labs, a UK supplier of laboratory research peptides. We're telling you that here, not in small print at the bottom of the page, because a site explaining how to read evidence critically should survive the same scrutiny it asks of everything else. Funding comes from the company; editorial judgement about what the evidence shows does not change because of who's paying for the lights to stay on. Where a claim here can't be supported by the literature, we say so — including when that's inconvenient.
Every page on this site follows the same structure: Claim → Source → Evidence → Limitations → Unknowns. We cite primary sources (original studies, registry records, regulator documentation) rather than secondary summaries where possible, distinguish laboratory and animal evidence from human evidence explicitly, and mark anything we couldn't verify rather than guess at it. Negative, inconclusive, or missing results get the same space as positive ones — see the Evidence Library and Clinical Trials Tracker for this in practice.
What we're reading and writing about
Short write-ups on notable published findings — what the study actually tested, in what model, and what it does and doesn't tell us.
Compound research briefs
First entries are in progress — each one will link back to the actual paper it's describing.
Methodology notes
Short explainers on study design — sample size, controls, model organism — for readers who want to judge a study's weight themselves.
Corrections & updates
Where new evidence changes a previous write-up, we'll say so here rather than quietly editing the original.
Looking for substantive content right now, not a short-form brief? Start with the Compound Deep Dives or the Evidence Library — both are live.
BPC-157
One compound, examined properly — what's actually been studied, and the evidence gap that gets glossed over almost everywhere else it's discussed.
A synthetic peptide with a well-documented preclinical literature — and almost no human trial data
BPC-157 is a synthetic pentadecapeptide based on a partial sequence identified in human gastric juice. It's one of the more extensively studied compounds in this space at the preclinical level, which makes it a useful example of a broader pattern: a large, genuinely interesting animal literature, and a human evidence base that hasn't caught up to it.
Where the evidence is established
A substantial body of rodent and in-vitro research has examined BPC-157 across models of tendon, ligament, muscle, and gastrointestinal tissue repair, generally focused on angiogenesis and cytoprotective signalling pathways. This is real, published, peer-reviewed preclinical literature — it's just animal and cell-model evidence, not human evidence.
Where the evidence is weak or absent
Robust, peer-reviewed human clinical trial data is largely absent. Most claims about effects in people circulating online are extrapolated directly from the animal literature above — which is exactly the kind of leap a careful reading of the evidence should flag, not smooth over.
How we classify evidence
Every compound we cover gets placed on this scale — it's the same framework behind the deep dive above, applied consistently rather than invented per-article.
Two compound profiles are live now, with more being added on the same verification standard — quality over quantity. Browse the Evidence Library →
How to actually read a trial
We're not going to list trials here that we can't stand behind. What's more useful right now is understanding how to check for yourself.
What a trial phase means
Phase I tests safety in a small group. Phase II looks at effect and dosing in a larger group. Phase III compares it against existing treatment or placebo at scale. Most compounds discussed in this space, including BPC-157, have never reached a registered Phase I trial in humans.
Where to check yourself
ClinicalTrials.gov is the public US registry of registered trials worldwide. If a compound has genuine human trial activity, it should show up there — searching it directly is more reliable than taking anyone's word for it, including ours.
Browse the Clinical Trials Tracker → — 11 verified registered trials across 5 compounds, with direct links to every registry record.
Independent researcher & clinician perspective
We haven't published commentary from named researchers or clinicians yet
When we do, it will be a real, attributed conversation with someone independent — not a quote written for them. No commentary on this site implies anyone's endorsement of Reliable Research Labs specifically unless that's a documented, on-the-record fact.
A short, honest primer
Four ideas that do more to help you evaluate a claim than any single study summary.
Preclinical vs. clinical
"Preclinical" means cell cultures or animal models — it's where almost all research starts, and where most research peptides currently sit. "Clinical" means human trials. The gap between the two is large and compounds frequently fail to cross it.
What peer review checks — and doesn't
Peer review means other scientists checked the methodology before publication. It doesn't mean the finding is proven, replicated, or generalisable — just that it cleared a baseline quality bar.
Why animal results don't always translate
Rodent physiology differs from human physiology in dosing, metabolism, and relevant biology. A strong effect in mice is a reason to study something further in humans — not evidence it works the same way in people.
Correlation vs. causation
A compound being present when an outcome improves doesn't mean the compound caused it. Controlled trials exist specifically to separate the two — which is why their absence matters.
What a Certificate of Analysis actually tells you
A Certificate of Analysis (COA) is a third-party lab report confirming what's actually in a vial — typically using HPLC (high-performance liquid chromatography) to check identity and purity, sometimes alongside mass spectrometry to confirm molecular structure. A COA tells you the product matches its label. It does not tell you the compound is safe, effective, or approved for human use — those are separate questions a purity test can't answer.
When you're comparing suppliers, a COA is a reasonable baseline to ask for. It's not a substitute for understanding what the underlying research does and doesn't show, which is the gap the rest of this site is trying to fill.
Where research peptides actually sit, legally
In the UK, research peptides are not licensed medicines. They haven't been evaluated or approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in humans or animals, and they're not legally sold as medicines, supplements, or consumer healthcare products. Legitimate suppliers sell them strictly for laboratory and research use, which is a real regulatory position, not just a disclaimer on a website.
That distinction matters when you're reading anything about these compounds, including this site: research-use status isn't a technicality to work around, it's an accurate description of where the evidence and the regulatory record currently stand.
Read the full guide: Peptides, Research Compounds & UK Regulation →
Reliable Research Labs
Reliable Research Labs is a UK supplier of laboratory-grade research peptides, and the company that funds The Primary Source. They're also the subject of a longer, separately-published conversation with their founder about running a supply business in this space — worth reading if you want more context on who's behind this page.
reliableresearchlabs.co.uk → · Read the founder interview on The Synthesis →